The request follows a similar move by Eli Lilly, which has asked for a ban on ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

We recently compiled a list of the Billionaire Ken Fisher’s Top 10 High Growth Stock Picks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. The start of mid-stage testing of PF-07081532 triggers a $10 million ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

1 Eli Lilly and ... and $61.0 billion. Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!